Current and Future Treatment Options in the Management of Stage III NSCLC von Li, Yuchen, Juergens, Rosalyn Anne, Finley, Christian, Swaminath, Anand

Volltext

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, con... von Kowalski, Dariusz M, Cho, Byoung Chul, Lubiniecki, Gregory M, Kush, Debra, Lopes, Gilberto, Adamchuk, Grigory, Ahn, Myung-Ju, Altundag, Ozden, Aoe, Keisuke, Ativitavas, Touch, Beato, Carlos, Bergstrom, Per, Betticher, Daniel, Buddu, Sayeuri, Castro, Hugo, Cay Senler, Filiz, Cerny, Carlos Alexandre Sydow, Chan, Gee-Chen, Chang, Jianhua, Cheng, Susanna, Cherciu, Nelly, Cho, Byoung Chul, Cicenas, Saulius, Cohen, Graham, Costa, Marcos Andre, De Angelis, Flavia, de Azevedo, Sergio Jobim, De Marchi, Pedro Rafael Martins, de The Bustamante Valles, Flor, Doganov, Boyan, Dreosti, Lydia, Duarte, Ricardo, Erman, Mustafa, Fein, Luis, Feng, Jifeng, Fenton, David, Fernandes, Gustavo, Ferreira, Carlos, Fujisaka, Yasuhito, Galvez, Christina, Gil, Nuno, Hall, Jacqueline, Hart, Gregory, He, Yong, Ho, Chung Man James, Horiike, Atsushi, Hu, Yi, Ichiki, Masao, Imamura, Fumio, Jassem, Jacek, Jordaan, Christa, Kaen, Diego, Katakami, Nobuyuki, Kato, Terufumi, Kawaguchi, Tomoya, Kim, Joo Hang, Kowalyszyn, Ruben, Ksienski, Doran, Kubota, Kaoru, Kuusk, Gerli, Laczo, Ibolya, Landers, Gregory, Lazarev, Sergey, Li, Wei, Liu, Zhe, Lopes, Valeria, Lu, Shun, Mas, Luis, Milanova, Zhasmina, Nakahara, Yasuharu, Ohman, Ronny, Ong, Choo Khoon, Ostoros, Gyula, Qin, Shukui, Ramlau, Rodryg, Richardet, Eduardo, Roubec, Jaromir, Rusyn, Andrii, Seki, Nobuhiko, Shimada, Andrea Kazumi, Shparyk, Yaroslav, Sinielnikov, Ivan, Soares, Joao Paulo Holanda, Stara, Zinaida, Tanaka, Hiroshi, Tang, Qiyou, Taranov, Pavel, Tejada, Hermes, Torii, Yoshitaro, Trukhyn, Dmytro, Turdean, Maria, Vera, Luis, Vynnychenko, Ihor, Wang, Jie, Wang, Kai, Yumuk, Fulden, Zambrano, Angela, Zemaitis, Marius, Zhao, Jun, Zhou, Jianying

Volltext

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results von Anagnostou, Valsamo, Ho, Cheryl, Nicholas, Garth, Juergens, Rosalyn Anne, Sacher, Adrian, Fung, Andrea S., Wheatley-Price, Paul, Laurie, Scott A., Levy, Benjamin, Brahmer, Julie R., Balan, Archana, Niknafs, Noushin, Avrutin, Egor, Zhu, Liting, Sausen, Mark, Bradbury, Penelope A., O’Donnell-Tormey, Jill, Gaudreau, Pierre Olivier, Ding, Keyue, Dancey, Janet

Volltext

Moving Through Inertia - The Promise of Current and Future Treatment Options in the Management of Stage III Non-Small Cell Lung Cancer von Li, Yuchen, Juergens, Rosalyn Anne, Finley, Christian, Swaminath, Anand

Volltext

Abstract CT212: A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of... von Anagnostou, Valsamo K., Ho, Cheryl, Nicholas, Garth, Juergens, Rosalyn Anne, Sacher, Adrian, Fung, Andrea, Wheatley-Price, Paul, Laurie, Scott, Levy, Benjamin, Brahmer, Julie, Balan, Archana, Niknafs, Noushin, Avrutin, Egor, Zhu, Liting, Sausen, Mark, Bradbury, Penelope, O'Donnell-Tormey, Jill, Gaudreau, Pierre-Olivier, Ding, Keyue, Dancey, Janet

Volltext

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC von Ramalingam, Suresh S, Vansteenkiste, Johan, Planchard, David, Cho, Byoung Chul, Gray, Jhanelle E, Ohe, Yuichiro, Zhou, Caicun, Reungwetwattana, Thanyanan, Cheng, Ying, Chewaskulyong, Busyamas, Shah, Riyaz, Cobo, Manuel, Lee, Ki Hyeong, Cheema, Parneet, Tiseo, Marcello, John, Thomas, Lin, Meng-Chih, Imamura, Fumio, Kurata, Takayasu, Todd, Alexander, Hodge, Rachel, Saggese, Matilde, Rukazenkov, Yuri, Soria, Jean-Charles

Volltext

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer von Soria, Jean-Charles, Ohe, Yuichiro, Vansteenkiste, Johan, Reungwetwattana, Thanyanan, Chewaskulyong, Busyamas, Lee, Ki Hyeong, Dechaphunkul, Arunee, Imamura, Fumio, Nogami, Naoyuki, Kurata, Takayasu, Okamoto, Isamu, Zhou, Caicun, Cho, Byoung Chul, Cheng, Ying, Cho, Eun Kyung, Voon, Pei Jye, Planchard, David, Su, Wu-Chou, Gray, Jhanelle E, Lee, Siow-Ming, Hodge, Rachel, Marotti, Marcelo, Rukazenkov, Yuri, Ramalingam, Suresh S

Volltext

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study von Garassino, Marina Chiara, Kim, Joo-Hang, Corral Jaime, Jesus, Powderly, John, Bidoli, Paolo, Wheatley-Price, Paul, Park, Keunchil, Wadsworth, Catherine, Dennis, Phillip A, Rizvi, Naiyer A, Paz-Ares Rodriguez, Luis, Novello, Silvia, Hiret, Sandrine, Schmid, Peter, Laack, Eckart, Califano, Raffaele, Vicente Baz, David, Berghmans, Thierry, Kim, Dong-Wan, Surmont, Veerle, Reck, Martin, Han, Ji-Youn, Holgado Martin, Esther, Chella, Antonio, Chopra, Akhil, Robinet, Gilles, Soto Parra, Hector, Thomas, Michael, Katakami, Nobuyuki, Su, Wu-Chou, Kim, Young-Chul, Lee, Jong-Seok, Saka, Hideo, Milella, Michele, Ramos Garcia, Inmaculada, Sibille, Anne, Atagi, Shinji, Spaeth-Schwalbe, Ernst, Nishio, Makoto, Imamura, Fumio, Derijcke, Sofie, Maeda, Tadashi, Zylla, Dylan, Santoro, Armando, Uy, Ma. Noemi, Lucien Geater, Sarayut, Kowalski, Dariusz, Chen, Yuh-Min, Spigel, David, Chewaskulyong, Busyamas, Garcia Gomez, Ramon, Alvarez Alvarez, Rosa, Yang, Chih-Hsin, Denis, Fabrice, Sakai, Hiroshi, Canon, Jean-Luc, Scholz, Christian, Kemmotsu, Hirotsugu, Azuma, Koichi, Feld, Ronald, Jassem, Jacek, Kubota, Kaoru, Waterhouse, David, Coudert, Bruno, Mark, Zsuzsanna, Chang, Gee-Chen, Herzmann, Christian, Chaudhry, Arvind, Giridharan, Selvaraj, Hesketh, Paul, Boccia, Ralph, Iannotti, Nichola, Haigentz, Missak, Reynolds, John, Nakagawa, Kazuhiko, Sugawara, Shunichi, Tan, Eng Huat, Takeda, Koji, Mohn-Staudner, Andrea, Panwalkar, Amit, Daniel, Davey, Kobayashi, Kunihiko, Ladrera, Guia Elena Imelda, Coupkova, Helena, Havel, Libor, Singh, Joginder, Murakami, Shuji, Anderson, Ian, Iqbal, Mussawar, Torri, Vamsee, Juhasz, Erzsebet, Koubkova, Leona, Levy, Benjamin, Page, Ray, Crinò, Lucio, Einspahr, David, Hagenstad, Christopher, Juat, Necy, Overton, Lindsay, Szalai, Zsuzsanna

Volltext

BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study von Chu, Quincy, Leighl, Natasha B., Surmont, Veerle, van Herpen, Carla, Sibille, Anne, Markman, Ben, Clarke, Stephen, Juergens, Rosalyn A., Rivera, Mirelis Acosta, Andelkovic, Vladimir, Rudin, Charles M., Snow, Stephanie, Kim, Dong-Wan, Sanatani, Michael, Lin, Hongxia, Sanghavi, Kinjal, Tannenbaum-Dvir, Sarah, Basciano, Paul, Lathers, Deanne, Urbanska, Katarzyna, Kollia, Georgia, He, Chunsheng, DiPiero, Andrew, Liu, Yu, Ready, Neal

Volltext

Phase II study of TAS‐106 in patients with platinum‐failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer von Tsao, Anne, Hui, Edwin Pun, Juergens, Rosalyn, Marur, Shanthi, Huat, Tan Eng, Cher, Goh Boon, Hong, Ruey‐Long, Hong, Waun Ki, Chan, Anthony Tak‐Cheung

Volltext